Patent application number | Description | Published |
20120021998 | Cancer Diagnosis and Treatment Methods of Use - The present invention relates to a method for treating a subject suffering from growth of AR-containing tumor cells, comprising administrating the subject an effective amount of DDB2. The present invention also relates to a kit for the diagnosis of cancer. | 01-26-2012 |
20120065122 | Pharmaceutical Composition and Method for Modulating Slow Myosin - The present invention directed to a method for modulating the expression level of slow myosin comprising administering to a subject in need thereof a therapeutically effective amount of nuclear receptor interaction protein (NRIP) modulator and calmodulin, and a pharmaceutically acceptable carrier. | 03-15-2012 |
20130081148 | NRIP KNOCKOUT MICE AND USES THEREOF - The present invention directs to a transgenic NRIP knockout mouse, the genome of which is manipulated to comprise a disruption of a nuclear receptor interaction protein (NRIP) gene, wherein the NRIP gene is disrupted by deletion of exon 2, the mouse exhibits a phenotype comprising abnormal muscular function. The present invention also directs to a method for making a transgenic NRIP knockout mouse whose genome comprises a homozygous disruption of the NRIP gene, the mouse exhibits abnormal muscular function. | 03-28-2013 |
20130178410 | METHODS FOR MODULATING SLOW MYOSIN - The present invention provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. The present invention also provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is an adenoviral vector. | 07-11-2013 |
20130184224 | METHODS FOR INHIBITING TUMOR GROWTH - The present invention provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. The present invention also provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is a plasmid vector. | 07-18-2013 |
20150226750 | NRIP AS A BIOMARKER OF ABNORMAL FUNCTION OF MOTOR NEURONS - The present invention provides a method for evaluating physiological state of motor neurons in a subject. The method comprises detecting an expression level of a nuclear receptor interaction protein (NRIP) in a biological sample from the subject; and comparing the expression level of the NRIP to a control value for NRIP; wherein detecting a decrease of the expression level of the NRIP in the biological sample from the subject as compared to the control value for NRIP indicates an abnormal function of the motor neurons of the subject | 08-13-2015 |